Æterna Zentaris P/E Adelante
¿Qué es el P/E Adelante de Æterna Zentaris?
El P/E Adelante de Æterna Zentaris, Inc. es -1.95
¿Cuál es la definición de P/E Adelante?
La relación precio a futuro es la relación entre el precio de las acciones de una empresa y las ganancias por acción estimadas de la compañía para los próximos doce meses.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
P/E Adelante de compañías en Sector Health Care en TSX en comparadas con Æterna Zentaris
¿Qué hace Æterna Zentaris?
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Empresas con p/e adelante similar a Æterna Zentaris
- Kaleyra Inc tiene P/E Adelante de -2.05
- Fermentalg SA tiene P/E Adelante de -2.04
- MeiraGTx plc tiene P/E Adelante de -2.02
- uniQure N.V tiene P/E Adelante de -2.00
- IntelGenx Technologies tiene P/E Adelante de -2.00
- COSCIENS Biopharma tiene P/E Adelante de -1.95
- Æterna Zentaris tiene P/E Adelante de -1.95
- Heat Biologics Inc tiene P/E Adelante de -1.94
- Retail Value Inc tiene P/E Adelante de -1.92
- vTv Therapeutics Inc tiene P/E Adelante de -1.89
- Eastside Distilling Inc tiene P/E Adelante de -1.88
- GVK Power & Infrastructure tiene P/E Adelante de -1.87
- Clearside Biomedical Inc tiene P/E Adelante de -1.87